Bivalirudin in Late PCI for Oatients With STEMI

• Status: Not yet recruiting
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Bivalirudin is recomended by guidelines during primary PCI procedure for patients with STEMI. However, there is a large number of STEMI patients who missed the primary PCI. So the investigators aim to study the efficiency and safety of bivalirudin as the anticoagulation therapy during late PCI.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second Xiangya Hospital of Central South University
• Treatments: Antithrombins; Bivalirudin; Calcium heparin; Heparin; Hirudins; Thrombin

Criteria

Inclusion Criteria:

1. Patients aged over 18 years.

2. Patients with ST-segment elevation MI (STEMI) undergoing late PCI 24 hours to 2 weeks after symptom onset. STEMI was defined as ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle branch block.

3. Patients with develop Q-waves at presentation and with clear culprit vessel confirmed by angiography or other clinical evidences.

4. No any other anticoagulation therapy 12 hours before late PCI.

Exclusion Criteria:

• STEMI patients undergoing primary PCI in 24 hours after symptom attack; patient unwilling or unable to provide written informed consent. thrombolytic therapy administered before randomization; any condition making PCI unsuitable or that might interfere with study adherence;